Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nitroglycerin, Fluorescent Angiography, and iVAC on Mastectomy Skin Flap Perfusion
NCT03716050Phase 3Terminated
- Sponsor
- Wake Forest University Health Sciences
- Start
- Jan 2018
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nitroglycerin in perfusion-related complication (8 arms), sponsored by Wake Forest University Health Sciences. Primary endpoints: Number of Soft Tissue Ischemia/Loss at 30 days, Number of Participants With Surgical Site Infection at 30 days and 1 more. Started Jan 2018; status: terminated.
02
Drugs
nitroglycerin
03
Conditions
perfusion-related complication
Beyond the preview
Go deeper on NCT03716050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03716050.